Clinical safety of a viral vector based prostate cancer vaccine strategy.

@article{Arlen2007ClinicalSO,
  title={Clinical safety of a viral vector based prostate cancer vaccine strategy.},
  author={Philip M. Arlen and Lisa Skarupa and Mary P Pazdur and Mahesh Seetharam and Kwong Yok Tsang and Douglas W. Grosenbach and Jarett L. Feldman and Diane J. Poole and Mary T. Litzinger and Seth M Steinberg and Elizabeth C. Jones and Clara Xiaoling Chen and Jennifer L. Mart{\'e} and Howard L. Parnes and John Joseph Wright and William Dahut and Jeffrey Schlom and James L. Gulley},
  journal={The Journal of urology},
  year={2007},
  volume={178 4 Pt 1},
  pages={
          1515-20
        }
}
PURPOSE The primary objective of this phase I study was to evaluate the clinical safety of a vaccine using recombinant vaccinia virus (prime) and recombinant fowlpox virus (boost) in combination with granulocyte-macrophage colony-stimulating factor in patients with prostate cancer. The vaccines contained transgenes for prostate specific antigen, a triad of co-stimulatory molecules and a tumor antigen whose amino acid sequence had been modified to enhance its immunogenicity. Secondary end points… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 55 CITATIONS, ESTIMATED 38% COVERAGE

Exploiting the Immunological Effects of Standard Treatments in Prostate Cancer

VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1993
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations